Women’s Health
Patient-centric solutions for your women’s health trial
Engaging women on a personal level to bridge translational gaps, overcome diagnostic challenges and drive recruitment and retention.
Patient-centric engagement
Experience rapid patient recruitment and high retention through therapy-specific outreach, advocacy group partnerships and voice of patient programs.
Seamlessly moving you forward
Advance your trial with our medical, scientific and operational OB-GYN expertise. Ensure seamless transitions with our early- to late-stage planning.
Innovative solutions
Leverage our DCT solutions, unique data assets and proprietary Xcellerate® platform to advance your women’s health trials.
Personalized solutions for women’s health
Fortrea bridges translational gaps, overcomes diagnostic challenges and optimizes recruitment and retention for superior trial experience. Focusing on critical path activities and proactive planning, we accelerate startup processes and improve timelines, cost and efficiency. We help our customers advance health equity and address unmet clinical needs in women’s health through exceptional drug and device development. We drive patient-centric practices and nurture bold ideas, fostering productive partnerships and a collaborative culture.
Enhancing enrollment and recruitment
We accelerate treatment delivery using our unique global data assets, real-world intelligence, proprietary technology platform and patient-centric DCT solutions. Our comprehensive data analytics, in-depth site knowledge of sites and strong relationships with sites and key opinion leaders (KOLs) allow us to predict your recruitment rates and address potential issues, resulting in better study design, faster startup and reduced risk.
Empowering and engaging women
Enable opportunities for clinical trial recruitment, patient registries, retrospective studies and prospective surveillance studies using our global experience and powerful patient-centric solutions in women’s health trials:
- Therapy-specific recruitment outreach platforms
- Advocacy group partnerships
- Women’s health educational content
- 1:1 coaching from registered nurses
- Voice of the Patient program for engagement and compliance
- Decentralization strategies for screening and study visits
Women’s health experience that matters
In the last 5 years, we have supported:
Data covers the period from 2020 through 2024.
Top indications
-
Endometriosis
-
Contraception
-
Reproductive Disorders
-
Fibroids
-
Preeclampsia
Our experts
Delivering women's health leadership
An exceptional partnership starts with an experienced team. Browse the bios of our featured team members.
Friedrich Wieser, MD
Medical Director
Friedrich (Fritz) Wieser, MD, is an OB/GYN who received his MD from the Vienna Medical University (Vienna, Austria). After completing his gynecology residency at the Dept. of Gynecology at the University Hospital in Vienna, he did a fellowship in Reproductive Medicine at UCSF in San Francisco, CA.
Dr. Wieser has over 20 years of clinical and research experience in a broad range of indications including endometriosis, fibroids, menopause, contraception, gynecological cancer and medical devices.
Before joining Fortrea as Medical Director, Dr. Wieser was a Global Medical Director at Merck KGaA (Darmstadt, GE) and served as Assistant Professor in the Department of Obstetrics and Gynecology at Emory University School of Medicine in Atlanta, Georgia. During that time, Dr. Wieser served as an NIH-funded investigator and sub-investigator for many gynecology studies and lead several global women’s health programs.
Olga Bodriagova, MD, PhD
Medical Director
Olga Bodriagova, MD, PhD, is a Medical Director in Oncology for Fortrea Clinical Development Services, based in Kyiv, Ukraine. Dr. Bodriagova has more than 20 years of experience in oncology clinical drug development as an Investigator, CRA and Medical Monitor in all phases of clinical development projects from early phase to post approval in different therapeutic areas, mainly oncology and women’s health. Dr. Bodriagova is serving as global lead project physician, providing medical and safety monitoring on assigned projects.
Dr. Bodriagova earned her medical degree from the Kyiv Medical Institute in Ukraine and completed OB/GYN residency at the Kyiv City Hospital #2. Dr. Bodriagova received an oncogynecology certification from the Kyiv Institute of Postgraduate and defended her PhD thesis in the field of endocrine gynecology. She joined our company in 2014.
Publications
- Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
- Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
Jeanelle Kam, MD
Medical Director, CPS Medical & Scientific Affairs
Jeanelle Kam, MD, is a trained OB/GYN with more than a decade of CRU drug development experience across multiple indications. As a CPI and Medical Director at the Phase I Dallas CRU, Dr. Kam conducted over 200 trials in BE, DDI, FE, FIH, Japanese Bridging and TQT studies. In 2022, she joined the CPS Medical Scientific Team as a Phase I Medical Monitor. Her expertise in Women’s Reproductive Health include serving as PI on OC-DDI studies, consultation of endometriosis, lactation and post-menopausal studies. She was the lead author for Fortrea’s birth control guidance, “Evidence-Based Guidance for Contraceptive Use in Phase I and Clinical Pharmacology Trials Including Women of Child-Bearing Potential” and presentation of the guidance at the 2015 Annual Meeting for ACCP poster session.
Supporting early- to late-stage continuity
As your compound advances from early- to late-stage clinical, we apply our established methods to ensure that successes, lessons learned and general information transfer across the drug development spectrum. Our approach reduces delays, minimizes data loss and increases awareness among our late-phase team. With this level of comprehension, we can enhance continuity and inform key adjustments concerning site monitoring activities and patient care requirements.
Our established methods and relationships with KOLs and site personnel enhance startup times and site performance. And when challenges arise―which they will―our proactive, solution-oriented team transparently shares strategies to address challenges, ensuring continuity across the drug development spectrum.
